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COMBINED RISK-FACTOR ANALYSIS PREDICTS OUTCOME OF AML PA-
TIENTS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION FOLLOW-
ING REDUCED INTENSITY CONDITIONING
Hemmati, P.G.1, Terwey, T.H.1, Massenkeil, G.2, le Coutre, P.1,
Neuburger, S.1, Dorken, B.1, Arnold, R.1 1Charite University Medicine
Berlin, Berlin, Germany; 2Guetersloh General Hospital, Guetersloh,
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Reduced intensity conditioning (RIC) allowed to offer allogeneic
stem cell transplantation (alloSCT) to patients ineligible to standard
conditioning. In addition to a number of disease-specific variables,
the presence of comorbidities, as assessed by the hematopoietic
cell transplantation-specific comorbidity index (HCT-CI), and
transplantation-associated factors affect the outcome of these
patients following allSCT.We therefore investigatedwhether a com-
bined risk-factor analysis predicts the overall outcome of patients
with AML following RIC-alloSCT. 90 patients with AML who
underwent alloSCT at our institution were analyzed. 50/90 patients
(56%) were in CR1, 12/90 (15%) were in .CR1, and 26/90 (29%)
had active disease. 4/90 patients (4%) had a favorable-risk karyotype,
51/90 patients (57%) or 29/90 patients (32%) had an intermediate-
risk or a poor-risk karyotype. 18/90 (20%) patients had an interme-
diate-risk HCT-CI and 72/90 patients (80%) had an unfavorable
score. 38/90 patients (42%) were transplanted from a matched-
related donor. A matched-unrelated or a mismatched-unrelated
donor was available in 36/90 patients (40%) or in 16/90 patients
(18%). As a preparative regimen all patients received RIC (fludara-
bine 180mg/m21 oral busulfane 8mg/kg1 antithymocyte globulin
40 mg/kg). Overall survival (OS) or disease-free survival (DFS) of all
patients at 1, 3, and 5 years was 60%, 44%, and 44% or 56%, 46%,
and 46%. 49/90 patients (54%) are in CR. Causes of death were
relapse (23/90 patients (26%)) or TRM (18/90 patients (20%)).
Depending on the presence or absence of at least one leukemia-
specific risk-factor (tAML, unfavorable-risk karyotype, .CR1) or
transplantation-related risk-factor (alloSCT from a mismatched or
an unrelated donor), patients were grouped into four subgroups:
group I (HCT-CI # 4, no high-risk), group II (HCT-CI .4, no
high-risk), group III (HCT-CI # 4, high-risk), and group IV
(HCT-CI .4, high-risk). Projected OS in at 1, 2, and 4 years after
alloSCT was 75%, 63%, and 63% (group I), 100%, 67%, and
67% (group II), 58%, 45%, and 36% (group III), or 31%, 15%,
and 15% (group IV), which differed significantly between the sub-
groups (p 5 0.01). There was no statistically significant difference
in TRM between the subgroups (p 5 0.27). This indicates that
a combined risk-factor analysis incorporating disease-specific vari-
ables, transplantation-related factors, and comorbidities may predict
the overall outcome of patients with AML after RIC-alloSCT.154
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Complete remission (CR) after chemotherapy for AML is defined
by\5% blasts in bone marrow (BM) and peripheral blood platelet
count .100K/ml. This remains the primary goal following chemo-
therapy; however, many patients proceed to HSCT without ever
achieving the platelet goal (CRp). With new therapies, the
number of patients transplanted in CRp is increasing. We sought
to determine if CRp was a worse prognosticator compared to
classically-defined CR.
Methods: A cohort of 427 patients was used. Disease status at
HSCT included: first CR (CR1); second CR (CR2); first CRp
(CRp1): patients with \5% BM blasts but not platelet recovery
following induction chemotherapy; primary induction failure
(PIF): no CR following induction therapy; CRp2: patients who after
therapy for first relapse achieved\5% BM blasts but not platelet
recovery; refractory (rel): patients in first relapse not responding to
salvage therapy. CRp was assigned only if patients were thrombocy-
topenic $30 days from the last day of chemotherapy to the start ofHSCT conditioning. Diagnoses included AML (n 5 376) or high-
risk MDS (n 5 51). Conditioning regimens used: TBI-based (2%;
n 5 8), oral/IV busulfan based-ablative regimens (61%; n 5 261),
fludarabine/melphalan-based reduced intensity conditioning regi-
mens (RIC) (36%; n5 153), or other (1%; n5 5). Fifty-eight percent
(n5 248) and 42% (n5 179) of patients received matched sibling or
unrelated donor (UD) HSCT, respectively
Results:Median age was 50 years (range 6–74). At time of HSCT,
disease status was CR1 in 38% (n 5 164), CR2 in 24% (n 5 102),
CRp1 in 11% (n 5 48), CRp2 in 7% (n 5 30), PIF 11% (n 5 47),
and rel1 8% (n5 36). Poor-risk cytogenetics were evenly distributed
in patients in CR1 (39%) Vs. CRp1 (44%) and in CR2 (15%) Vs.
CRp2 (24%). Fifty-one percent of patients died (n 5 219); 31%
(n 5 134) progressed. Overall survival (OS) at 36-months was
49%. Among survivors, median follow-up is 42 months (range 3–
131months). Hazard ratios for non-relapse mortality (NRM) and
OS at 1-year (Table) favored patients receiving HSCT in CR1 (vs.
CRp1 or PIF), or in CR2 (vs. CRp2 or rel1).
Conclusion: Significantly better OS and NRM were seen follow-
ing HSCT for patients in CR compared to CRp. CRp conferred an
intermediate prognostic status, better than refractory disease, but
significantly worse than ‘classic’ CR. Achieving a CR prior to
HSCT should remain the gold standard for patients with AML or
MDS receiving allogeneic HSCT.
Table. Hazard Ratios (HR) for non-relapse mortality (NRM)
and overall survival (OS) at 1 year. CR1 is used as the reference
group.
NRM OSCR1 (n5164) Reference Reference
CR2 (n5102) 1.4 (p50.3) 1.3 (p50.3)
CRp1 (n548) 2.4 (p50.01) 2.4 (p50.001)
CRp2 (n530) 1.7 (p50.2) 1.9 (p50.05)
PIF (n547) 3.7 (p50.001) 3.6 (p50.001)
First relapse (n536) 4.6 (p50.001) 6.7 (p50.001)CR5complete remission; CRp5pathologic CR; PIF5primary induction
failure.155
POLYCLONAL PRAME-SPECIFIC CYTOTOXIC T LYMPHOCYTES GENER-
ATED USING PROTEIN-SPANNING POOLS OF OVERLAPPING PENTADE-
CAPEPTIDES TARGET CHRONIC MYELOID LEUKEMIA
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Following allogeneic hematopoietic stem cell transplantation,
GVL is likely mediated not only by alloreactive T cells, but also
by donor lymphocytes recognizing tumor associated antigens over-
expressed by leukemic cells. Selective expansion of tumor-specific
CTLs could augment GVL without increasing the risk of
GVHD. The cancer testis antigen PRAME is a potential target
for adoptive immunotherapy of hematologic and solid tumors.
We have shown that PRAME-CTL can be expanded ex vivo, using
a combination of artificial antigen presenting cells (aAPC) (K562
cell line genetically modified to express the HLA-A*02 and costi-
mulatory molecules) and cytokines. Four HLA-A*02 PRAME-de-
rived epitopes have previously been identified using a proteosome
mediated digestion analysis, that relying only on the major cleavage
site of the immune proteosome, may limit their relevance. We have
now adopted a method that uses a 125 overlapping pentadecapep-
tides library spanning whole PRAME protein. We evaluated
whether novel immunogenic HLA-A*02-restricted epitopes can
be identified and used to consistently generate polyclonal
PRAME-CTL lines from healthy donors and patients with hema-
tologic malignancies. CD81 T cells from 14 healthy donors and
5 patients with chronic myelogenenous leukemia (CML) were
primed with autologous CD40L-activated B blasts loaded with
the PRAME library in the presence of IL12, IL7 and IL15, and
then expanded by weekly stimulation with peptide loaded aAPC
